Abstract The Alzheimer's Association hosted the second Latinos & Alzheimer's Symposium
in May 2021. Due to the COVID‐19 pandemic, the meeting was held online over 2 days, with …

Importance Underrepresentation of many racial/ethnic groups in Alzheimer disease (AD)
clinical trials limits generalizability of results and hinders opportunities to examine potential …

Objective Many factors contribute to inadequate diversity in Alzheimer disease (AD) clinical
trials. We evaluated eligibility rates among racial and ethnic groups at US sites in large …

Introduction This perspective paper addresses the US Hispanic/Latino (herein, Latino)
experience with regards to a significant public health concern—the underrepresentation of …

As the last opportunity to assess treatment effect modification in a controlled setting prior to
formal approval, clinical trials are a critical tool for understanding the safety and efficacy of …

Achieving health equity requires creating evidence that reflects the nuance and diversity of
experiences among populations disproportionately impacted by age-and race-related …

Alzheimer disease (AD) disproportionately affects women and people from racial and ethnic
minority groups and is an active area of therapeutic research to develop interventions that …

Introduction Remote, internet‐based methods for recruitment, screening, and longitudinally
assessing older adults have the potential to facilitate Alzheimer's disease (AD) clinical trials …

Background Primary progressive aphasia (PPA) is a clinical dementia syndrome.
Impairments in language (speaking, reading, writing, and understanding) are the primary …

Introduction Acculturation‐related characteristics, that is, factors directly connected to culture
and familial relationships, are associated with engaged research participation within Latino …